Route 1: manufacturer self-pay pharmacies
This is the first thing to price, and most people do not know it exists. Both manufacturers now sell direct to patients paying cash, at a fraction of list price.
Eli Lilly sells Zepbound® in single-dose vials through LillyDirect, in the region of $349 per month for the 2.5mg starting strength and $499 for higher strengths as of September 2026. The vials are drawn with a separate syringe rather than delivered by an autoinjector pen. Novo Nordisk sells Wegovy® and Ozempic® through NovoCare Pharmacy, its own self-pay channel, at around $499 per month as of the same date.
Both prices have moved more than once, so get the current figure from LillyDirect or NovoCare Pharmacy rather than from any article, including this one. Three things to know. You still need a valid prescription, because these channels dispense rather than diagnose. You cannot combine self-pay pricing with an insurance claim. And the price covers medication only, so your prescriber visit and follow-up are separate.
Route 2: manufacturer savings cards
With commercial insurance that covers the medication, a savings card can bring your cost to as little as $0 to $25 per month. With commercial insurance that does not cover it, the card usually still applies at a higher rate, in the region of $499 to $650 per month as of September 2026 depending on the product. Both manufacturers publish their current card terms, and those terms change, so read them at the source before you count on a figure.
The hard rule: manufacturer savings cards are closed to anyone with government insurance. Medicare, Medicaid, TRICARE, VA benefits and federal employee plans all disqualify you under federal anti-kickback rules, even when that plan does not cover the drug. It is the most common reason a card is declined at the counter.
Route 3: patient assistance programs
Both manufacturers run programs that provide medication at no cost to patients who qualify. These are genuinely free and genuinely hard to qualify for.
Typical requirements as of September 2026: US residency, no prescription drug coverage at all, household income below a threshold often set around 400% of the federal poverty level, and a prescriber who completes their portion of the application. Applications take a few weeks and renew annually. Each program publishes its own criteria, and they are revised, so read the current version before you invest time in it.
The important caveat: not every product is included, and weight management products in particular have moved in and out of eligibility. Confirm the current product list before investing time in an application. Where to check: Eli Lilly's patient assistance program through the Lilly Cares Foundation, Novo Nordisk's Patient Assistance Program, the independent nonprofit directories NeedyMeds and RxAssist, and your state pharmaceutical assistance program if your state operates one.
Route 4: discount cards and coupons
Be realistic about this one. Discount cards work by negotiating against generic competition, and brand GLP-1s have none, so for most of the past few years discount platforms saved people very little on Ozempic, Wegovy or Zepbound.
What has changed is that some platforms, GoodRx among them, now surface the manufacturer's own cash-pay price rather than a negotiated discount. That is worth checking, but understand what you are seeing: usually the same self-pay price from Route 1, reached through a different door. Compare what GoodRx shows against what LillyDirect or NovoCare Pharmacy shows on the same day. It costs nothing to do, and do not expect it to beat the manufacturer channel.
Route 5: appeal the denial
If you have insurance and it said no, find out which no you got, because they have different fixes.
A formulary exclusion means your plan does not cover the drug class at all. Appeals rarely succeed against a blanket exclusion, but a formulary exception request is still worth filing if your clinician can document medical necessity.
A failed prior authorization means the drug is covered but you did not meet the criteria as documented. This is the most fixable denial, and the gap is usually a missing BMI record, a missing comorbidity code, or no documented prior weight management attempts. Ask your prescriber's office to resubmit.
Step therapy means trying something else first. Ask what, for how long, and whether a documented intolerance satisfies the requirement.
A different indication may change the answer. Zepbound is approved for moderate to severe obstructive sleep apnea in adults with obesity, and Wegovy for reducing cardiovascular risk in adults with established cardiovascular disease who also have overweight or obesity. Some plans that exclude weight management medication will still cover under those indications. Only your plan can confirm, and only a clinician can determine whether either applies to you. Request your denial letter in writing, note the appeal deadline, and ask about external review rights. Our insurance coverage guide has the full script for these calls.
Route 6: ask whether a different medication fits
If the cost of a GLP-1 is genuinely out of reach, say so to a clinician rather than abandoning treatment.
Metformin is an older oral medication, generically available, and can cost under $30 a month at retail with a discount card as of September 2026. It works differently from GLP-1 medications, typically produces more modest effects, and is not appropriate for everyone, though for some patients, particularly with insulin resistance or PCOS, it is a reasonable option. Society offers metformin from $99 per month with clinician care included. If price is your constraint, the generic at a retail pharmacy is cheaper than that, and we would rather you knew. Whether any older weight management medication suits you is a clinical question for your prescriber.
.png){kind=avatar}
.png)
.png)
.svg)
.svg)
